Clinical studies

probiotik-enterobiotik-talas

Reference:

  1. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010; 16(18): 2202–2222.
  2. McFarland LV. Meta-analysis of probiotics for the prevention of Antibiotic Associated Diarrhea (AAD) and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006: 101; 1-11. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA.1994;271:1913-1918.
  3. Szajewska H. et al. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2015; 42: 793–801. http://www.ncbi.nlm.nih.gov/pubmed/26216624
  4. Szajewska H. et al. Systematic Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2015;41(12):1237-45. http://www.ncbi.nlm.nih.gov/pubmed/25898944
  5. Bentley C. Double-blind, randomized, placebo-controlled, multi-centric nutritional study to prove the efficacy and safety of a probiotic for common colds; Berlin, Dec 2008.
  6. Niedzil K. et al. Eur J Gastroenter. Hepatology. 2001; 13: 1143-47.
  7. Bengt K. et al. Use of the probiotic Lactobacillus plantarum 299 to reduce pathogenic bacteria in the oropharynx of intubated patients: a randomised controlled open pilot study. Critical Care 2008.12:R136.
  8. Molin G. Lactobacillus plantarum 299. Dept. Food Technology, Engineering and Nutrition, Lund University 2015-06-10. (http://probi.se/sites/all/files/attachment_files/lp_299-15_2015-06-10.pdf)